Form 4: Vanda Pharmaceuticals Director Anne Sempowski Ward Reports Acquisition and Disposal of Shares

Director Anne Sempowski Ward reports acquiring shares through restricted stock units and stock options, while disposing of existing shares.

Summary

• On May 17, 2024, Anne Sempowski Ward, a director of Vanda Pharmaceuticals Inc., reported transactions involving the company's common stock and stock options.
• Ward acquired 20,529 shares of common stock through a time-based restricted stock unit (RSU) award at a price of $0.
• These shares will vest on May 17, 2025, contingent upon continuous service to the Issuer.
• Ward also acquired 37,578 stock options with an exercise price of $5.48, which will vest on May 17, 2025, also contingent upon continuous service.
• Additionally, Ward disposed of 59,842 shares of common stock.
• Following these transactions, Ward beneficially owns 59,842 shares of common stock and 37,578 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The acquisition of shares and options is a positive sign, but the disposal of shares tempers the overall outlook. The vesting conditions also introduce an element of uncertainty.

Positives

• Acquisition of shares through restricted stock units and stock options indicates confidence in the company's future performance.

Negatives

• The disposal of 59,842 shares could be interpreted negatively, although the reason for disposal is not specified.

Risks

• The vesting of the restricted stock units and stock options is contingent upon continuous service, creating a potential risk if the director leaves the company before the vesting date.

Future Outlook

The vesting of RSUs and stock options on May 17, 2025, is contingent upon continuous service to the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge sentiment and potential future actions of key personnel.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the pharmaceutical industry.
• Comparing Ward's transactions to those of other directors in similar-sized pharmaceutical companies can provide insights into the relative attractiveness of Vanda Pharmaceuticals' stock.
• For example, if other directors in comparable companies are also acquiring shares, it could signal a positive industry trend.

Stakeholder Impact

• The transactions may influence investor perception of the company's stock.
• Employees may view the vesting of RSUs and stock options as a positive incentive.

Key Dates